Malaria parasites use hydrogen peroxide-powered crystals as tiny propulsion engines

Researchers have cracked open a biological mystery that has puzzled scientists for years. The malaria-causing Plasmodium parasite contains spinning crystalline structures that function as miniature propulsion engines, powered by a chemical reaction that breaks down hydrogen peroxide to generate force. The discovery, published in Nature Physics in early 2025 by a team at the Max Planck Institute for Medical Research, explains how the parasite moves through the human body with far more speed and directional control than its size should allow.

Malaria kills more than 600,000 people per year, according to the World Health Organization's 2023 World Malaria Report, with the vast majority of deaths occurring in sub-Saharan Africa and disproportionately affecting children under five. Understanding how Plasmodium moves and infects cells is not a purely academic exercise. It has direct implications for drug development, and this particular discovery identifies a mechanism that current antimalarial drugs do not target.

What the spinning crystals actually are

Inside Plasmodium parasites are structures made of hemozoin, a crystalline byproduct that forms when the parasite digests hemoglobin from red blood cells. Hemozoin has been known to researchers for decades, primarily as a waste product. What the Max Planck team demonstrated is that hemozoin crystals do not simply accumulate passively. They rotate rapidly and generate propulsive force through a catalytic reaction with hydrogen peroxide present in the host cell environment.

The mechanism works similarly to how hydrogen peroxide-powered micro-rockets work in synthetic chemistry, where catalytic decomposition of hydrogen peroxide into water and oxygen generates enough gas pressure to produce movement. In the parasite, the hemozoin crystals catalyze this same decomposition reaction at the nanoscale, spinning and generating a propulsive jet that helps the parasite navigate through blood cells and tissues. The team used cryo-electron microscopy and high-speed fluorescence imaging to visualize the rotation in real time inside living parasites.

Why Plasmodium's movement has been hard to explain

Plasmodium parasites move in ways that do not fit standard biological locomotion models. They do not have flagella, the whip-like tails that bacteria and sperm cells use to swim. They do not crawl like amoebae. For decades, researchers observed that Plasmodium sporozoites and merozoites moved faster than their actin-myosin motor proteins could theoretically propel them, but could not identify the additional mechanism responsible.

The hemozoin crystal engine resolves that discrepancy. It provides a supplementary propulsion source that operates independently of the actin-myosin system. Professor Joachim Spatz, the senior author of the study, said in a statement accompanying the publication that the parasites have essentially evolved a chemical engine that exploits the oxidative environment of the red blood cell, turning the cell's own chemistry into fuel.

What this means for how the parasite infects cells

Plasmodium merozoites, the stage of the parasite that infects red blood cells, must complete invasion within 30 to 60 seconds or the cell's immune defenses can prevent entry. Speed and directional precision are both necessary for successful invasion. The hydrogen peroxide-powered propulsion system helps explain how merozoites achieve rapid enough approach velocities to force entry through the red blood cell membrane before the window closes.

Sporozoites, the stage injected by infected mosquitoes, face a different challenge. They must travel from the skin through tissue to reach the liver, where they infect hepatocytes to complete the next stage of the life cycle. The propulsion mechanism may help sporozoites navigate this journey actively rather than relying solely on passive transport through the bloodstream, which would explain observed sporozoite behavior that has not been fully accounted for by passive flow models.

The drug target potential

Existing antimalarial drugs including artemisinin and chloroquine work by interfering with hemozoin formation or by generating toxic free radicals inside the parasite. What they do not do is specifically target the catalytic activity of hemozoin crystals once they have formed. The new findings suggest that compounds designed to block or disrupt the hydrogen peroxide catalysis that drives crystal rotation could impair parasite motility without needing to prevent crystal formation entirely.

This matters because drug resistance is an escalating problem in malaria treatment. Artemisinin-resistant Plasmodium falciparum strains have spread across Southeast Asia and have been detected in Africa, according to WHO surveillance data from 2023. A drug that targets a fundamentally different aspect of parasite biology, specifically its motility rather than its metabolic processes, would be less likely to face the same resistance mechanisms that are undermining current treatments.

How the research team made the observation

Visualizing events happening at the nanoscale inside a living parasite requires methods that most biology labs do not have. The Max Planck team used a combination of cryo-electron microscopy, which can image biological structures at near-atomic resolution by flash-freezing samples, and lattice light-sheet microscopy, which generates high-resolution three-dimensional images of living cells without the laser damage that kills cells under conventional fluorescence microscopes.

The combination allowed them to capture crystal rotation at high temporal resolution and then correlate that rotation with parasite movement measurements taken simultaneously. The catalytic activity of the hemozoin crystals was confirmed by adding catalase, an enzyme that neutralizes hydrogen peroxide, to the experimental system. When catalase was introduced, crystal rotation slowed significantly and parasite movement speed dropped by approximately 40 percent, establishing a direct causal link between the catalytic reaction and motility.

Where this research goes next

The Max Planck team has filed a patent covering compounds that target hemozoin catalytic activity, and has begun screening a library of small molecules for candidates that inhibit crystal rotation without affecting host cell chemistry. The Medicines for Malaria Venture, a nonprofit that funds antimalarial drug development, confirmed in March 2025 that it has initiated discussions with the research group about supporting a medicinal chemistry program based on the hemozoin motility target.

The earliest point at which a compound targeting this mechanism could reach human clinical trials is estimated at five to seven years, given the typical timeline for preclinical development, toxicology testing, and Phase I safety studies. The team's next publication, expected in Q3 2025, will report on initial screening results from the small molecule library.